These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 33075684)
21. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Yang Z; Jiang X BMC Gastroenterol; 2023 Apr; 23(1):122. PubMed ID: 37046191 [TBL] [Abstract][Full Text] [Related]
22. Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. Sumiyoshi T; Shima Y; Okabayashi T; Negoro Y; Shimada Y; Iwata J; Matsumoto M; Hata Y; Noda Y; Sui K; Sueda T World J Surg; 2018 Sep; 42(9):2910-2918. PubMed ID: 29511872 [TBL] [Abstract][Full Text] [Related]
23. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
25. Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature. Liu QQ; Yu XH; Tang QB; Chen D; Zhang R; Liu C; Shi XD Anticancer Drugs; 2024 Jan; 35(1):81-85. PubMed ID: 37227031 [TBL] [Abstract][Full Text] [Related]
26. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. Edeline J; Touchefeu Y; Guiu B; Farge O; Tougeron D; Baumgaertner I; Ayav A; Campillo-Gimenez B; Beuzit L; Pracht M; Lièvre A; Le Sourd S; Boudjema K; Rolland Y; Boucher E; Garin E JAMA Oncol; 2020 Jan; 6(1):51-59. PubMed ID: 31670746 [TBL] [Abstract][Full Text] [Related]
27. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease. van Keulen AM; Buettner S; Olthof PB; Klümpen HJ; Erdmann JI; Izquierdo-Sanchez L; Banales JM; Goeppert B; Roessler S; Zieniewicz K; Lamarca A; Valle JW; La Casta A; Hoogwater FJH; Donadon M; Scheiter A; Marzioni M; Adeva J; Kiudeliene E; Fernández JMU; Vidili G; Mocan T; Fabris L; Krawczyk M; Folseraas T; Dopazo C; Detry O; Voiosu T; Scripcariu V; Biancaniello F; Braconi C; Macias RIR; Groot Koerkamp B Ann Surg Oncol; 2024 Oct; 31(10):6495-6503. PubMed ID: 38896226 [TBL] [Abstract][Full Text] [Related]
28. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis. Tang Z; Yang Y; Zhao Z; Wei K; Meng W; Li X Medicine (Baltimore); 2018 Aug; 97(34):e11999. PubMed ID: 30142840 [TBL] [Abstract][Full Text] [Related]
30. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Choi SH; Kang I; Lee SH; Kang B; Cheon J; Kim DJ; Kim G; Kwon CI; Ko KH; Chon HJ Surgery; 2023 Feb; 173(2):280-288. PubMed ID: 36435652 [TBL] [Abstract][Full Text] [Related]
31. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213 [TBL] [Abstract][Full Text] [Related]
33. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621 [TBL] [Abstract][Full Text] [Related]
34. Does additional resection of a positive microscopic ductal margin benefit patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis. Ke Q; Chen Y; Huang Q; Lin N; Wang L; Liu J PLoS One; 2020; 15(5):e0232590. PubMed ID: 32379819 [TBL] [Abstract][Full Text] [Related]
35. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032 [TBL] [Abstract][Full Text] [Related]
36. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. Kim SH; Kim IH; Kim SW; Lee SO World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621 [TBL] [Abstract][Full Text] [Related]